Halozyme Overview
- Founded
-
1998
- Status
-
Public
- Employees
-
145
- Stock Symbol
-
HALO
- Investments
-
2
- Share Price
-
$51.12
- (As of Monday Closing)
Halozyme General Information
Description
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme utilizes a strategy that focuses on developing its own proprietary products in therapeutic areas with significant unmet medical needs, with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. The company's operations are based in the United States, with minimal long-lived assets located internationally.
Contact Information
Website
www.halozyme.com
Formerly Known As
Global Yacht Services
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Biotechnology
Other Industries
Drug Delivery
Stock Exchange
NAS
Primary Office
- 11388 Sorrento Valley Road
- San Diego, CA 92121
- United States
+1 (858) 000-0000
Halozyme Stock Performance
(As of Monday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $51.12 | $50.71 | $32.00 - $59.46 | $6.91B | 135M | 1.31M | $1.53 |
Halozyme Financials Summary
|
In Thousands, USD |
TTM 30-Sep-2022 | FY 2021 31-Dec-2021 | FY 2020 31-Dec-2020 | FY 2019 31-Dec-2019 |
|---|---|---|---|---|
| EV | 6,544,319 | 5,720,831 | 5,820,593 | 2,423,994 |
| Revenue | 580,623 | 443,310 | 267,594 | 195,992 |
| EBITDA | 290,669 | 259,044 | 152,964 | (56,556) |
| Net Income | 211,197 | 402,710 | 129,085 | (72,240) |
| Total Assets | 1,864,543 | 1,104,429 | 579,924 | 565,874 |
| Total Debt | 1,504,471 | 876,674 | 397,228 | 402,587 |
Public Fundamental Data provided by Morningstar, Inc.
disclaimer
Halozyme Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Halozyme Comparisons
Description
Primary
Industry
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Financing
Details
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies.
Biotechnology
San Diego, CA
145
As of 2021
00000
00000000
00000
00 000
velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupid
0000000000000
Durham, NC
000
As of 0000
00000
00000000
00000
00000
mpor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis
0000 000000000
San Diego, CA
000
As of 0000
00000
000000000
00000
Add Comparison
Halozyme Competitors (11)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| G1 Therapeutics | Formerly VC-backed | Durham, NC | 000 | 00000 | 00000000 | 00000 |
| 00000 000000000000 | Formerly VC-backed | San Diego, CA | 000 | 00000 | 000000000 | 00000 |
| 0000000-00000 0000 | Corporation | New York, NY | 00000 | 00000 | 00000000000 | 00000 |
| 0000000 0000000000 | Formerly VC-backed | Hampton, NJ | 000 | 00000 | 00000000 | 00000 |
| 00000 | Corporation | Basel, Switzerland | 000000 | 00.000 | 00000000000 | 00.000 |
Halozyme Patents
Halozyme Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20220233689-A1 | Methods of treating tumors | Pending | 28-Dec-2020 | 000000000000 | |
| US-20220233693-A1 | Antibody compositions and methods of use thereof | Pending | 28-Dec-2020 | 000000000000 | |
| US-20190351031-A1 | Methods of selecting subjects for combination cancer therapy with a polymer-conjugated soluble ph20 | Inactive | 16-May-2018 | 000000000 | |
| AU-2018236742-A1 | Compositions of adenosine deaminase-2 (ada2), variants thereof and methods of using same | Active | 14-Oct-2014 | 00000000 | |
| AU-2018236742-B2 | Compositions of adenosine deaminase-2 (ada2), variants thereof and methods of using same | Active | 14-Oct-2014 | C12N9/78 |
Halozyme Executive Team (38)
Halozyme Board Members (14)
| Name | Representing | Role | Since |
|---|---|---|---|
| Bernadette Connaughton | Halozyme | Board Member | 000 0000 |
| Connie Matsui | Self | Chairman & Board Member | 000 0000 |
| Helen Torley | Halozyme | President, Chief Executive Officer & Board Member | 000 0000 |
| James Daly | Self | Board Member | 000 0000 |
| Jean-Pierre Bizzari MD | Self | Board Member | 000 0000 |
Halozyme Signals
Growth Rate
0.80%
Weekly
Growth
Growth
Weekly Growth
0.80%, 93rd %
-35.5%.
530%
Size Multiple
219x
Median
Size Multiple
219x, 100th %ile
0.00x
0.95x.
413Kx
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
Halozyme Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Halozyme Acquisitions (2)
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| 0000000 00000 | 24-May-2022 | 0000000000 | 00.000 | Pharmaceuticals | 00000 000 |
| Global Yacht Services | 11-Mar-2004 | Merger/Acquisition | Other Services (B2C Non-Financial) |
Halozyme Subsidiaries (1)
| Company Name | Industry | Location | Founded |
|---|---|---|---|
| 0000000 000000 | Pharmaceuticals | Ewing, NJ | 0000 |
Halozyme ESG
Risk Overview
Risk Rating
Updated May, 18, 2022
23.76 | Med Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
00.0
Management
Management is related to actions taken to manage ESG issues
00.00
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
00 of 15,613
Rank
00.00
Percentile
Pharmaceuticals
Industry
00 of 1,004
Rank
00.00
Percentile
Biotechnology
Subindustry
00 of 462
Rank
00.00
Percentile
